Hikal Limited Announces 38th Annual General Meeting and Releases FY26 Annual Report
Hikal Limited released its Annual Report for FY26 and announced its 38th AGM. The report details INR 17,126 Million revenue and 13.6% EBITDA margin. Key developments include HPAPI lab operationalization and cGMP Pilot Plant commissioning. The company achieved an EcoVadis Gold Medal and aims for INR 500+ crore revenue from Personal Care by 2029-30.
This announcement is a routine disclosure of the annual report and AGM notice. It provides a summary of past performance and future outlook but does not contain any immediate, material events or changes that would significantly impact the company's stock or operations in the short term.
The announcement is primarily an update regarding the Annual Report and AGM, with financial performance details from the past fiscal year. While the report highlights achievements and future plans, it does not contain new, significant positive or negative news that would strongly sway sentiment.
Hikal Limited has announced its 38th Annual General Meeting (AGM) and has released its Annual Report for the financial year 2025-26. The company is sending these documents to its members via electronic mode, provided their email addresses are registered. For members whose email addresses are not registered, a letter will be sent providing a weblink to access the Annual Report from the company's website. The Annual Report and the Notice of the AGM are available on Hikal's website at the provided links.
The Annual Report highlights Hikal's progress in fiscal year 2025-26, emphasizing strengthened resilience and a focus on transformation. The company reported INR 17,126 Million in revenue with an EBITDA margin of 13.6%, and INR 3,021 Million in cash flow from operations. Key operational achievements include strengthening CDMO pipeline, operationalizing the High-Potency API (HPAPI) laboratory, commissioning a Kilo Lab, and advancing presence in animal health and specialty chemicals. Sustainability remains a core focus, with initiatives like product-level carbon footprint assessments and Scope 1, 2, and 3 GHG emissions accounting. Hikal also achieved an EcoVadis Gold Medal for sustainability performance and received the Safe-Tech Best Process Safety Excellence Award for its Taloja site.
The company's Pharmaceutical business showed a recovery, driven by improving demand and the operationalization of the HPAPI laboratory and cGMP Pilot Plant. The Crop Protection business saw steady recovery with improved customer demand and higher own product volumes. The Animal Health business gained momentum, and the company is expanding into Specialty Chemicals and Personal Care segments. Hikal aims to scale its Personal Care business to over INR 500 crore by 2029-30.
The company's strategic transformation initiative, Pinnacle 2.0, focuses on deeper customer engagement, strengthening the product and technology pipeline, and improving operational efficiency. Future plans include achieving an EcoVadis Platinum rating, continued growth in Crop Protection, overcoming challenges in Pharmaceuticals with a focus on DMF filings and niche products, and growing diversification strategies.
A plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.